Back to search

Article

Anti-tumor Activity of Cetuximab Plus Avelumab in Non-Small Cell Lung Cancer Patients Involves Innate Immunity Activation: Findings from the CAVE-Lung Trial

2022-01-17

Abstract excerpt

<h4>Background: </h4> We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1 drug, and cetuximab, an anti-epidermal growth factor receptor (EGFR) drug, as second- or third-line treatment in non-small cell lung cancer (NSCLC) patients. We have reported clinically rel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
898f72cf-6b3f-5cda-ab3c-03e2f2f7360f
DOI
10.21203/rs.3.rs-1254137/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Anti-tumor Activity of Cetuximab Plus Avelumab in Non-Small Cell Lung Cancer Patients Involves Innate Immunity Activation: Findings from the CAVE-Lung TrialDOI 10.21203/rs.3.rs-1254137/v1
An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti- angiogenic agents for therapy: a case reportSemantic proximity
Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations.Semantic proximity
An advanced IVB lung adenocarcinoma patient with KRAS mutations, benefited from camrelizumab combined with anti-angiogenic agents for therapy: a case reportSemantic proximity
Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumorsSemantic proximity
An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report.Semantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.Semantic proximity
Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.Semantic proximity
Real-world Data Analysis of Immunotherapy in Advanced Lung CancerSemantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Effects of anlotinib combined with second-line chemotherapy on the levels of immune cells and inflammatory factors and the curative effects in patients with advanced non-small cell lung cancerSemantic proximity
Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer.Semantic proximity
Select a neighboring publication to make it the new centre.